Zacks Research Issues Positive Outlook for BHC Earnings

Bausch Health Companies Inc. (NYSE:BHC) – Zacks Research upped their Q1 2025 earnings estimates for shares of Bausch Health Companies in a research report issued to clients and investors on Monday, January 20th. Zacks Research analyst R. Department now expects that the company will earn $0.87 per share for the quarter, up from their prior forecast of $0.85. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.73 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q2 2025 earnings at $1.04 EPS, Q4 2025 earnings at $1.17 EPS, Q1 2026 earnings at $1.10 EPS, Q2 2026 earnings at $1.15 EPS and Q3 2026 earnings at $1.38 EPS.

Bausch Health Companies (NYSE:BHC) last posted its earnings results on Wednesday, October 30th. The company reported $1.12 EPS for the quarter, topping the consensus estimate of $1.02 by $0.10. The firm had revenue of $2.51 billion during the quarter, compared to analysts’ expectations of $2.42 billion. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. Bausch Health Companies’s quarterly revenue was up 12.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.03 EPS.

A number of other research firms also recently commented on BHC. Royal Bank of Canada increased their price objective on Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a report on Friday, November 1st. Evercore ISI raised shares of Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th. Finally, StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $7.75.

Bausch Health Companies Trading Up 0.4 %

NYSE BHC opened at $7.47 on Wednesday. The stock’s 50-day moving average price is $7.88 and its two-hundred day moving average price is $7.45. The company has a market cap of $2.70 billion, a PE ratio of -15.56 and a beta of 0.69. Bausch Health Companies has a 1 year low of $3.96 and a 1 year high of $11.46.

Institutional Trading of Bausch Health Companies

Hedge funds have recently added to or reduced their stakes in the company. Mackenzie Financial Corp increased its stake in shares of Bausch Health Companies by 111.0% in the 2nd quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company’s stock valued at $16,612,000 after purchasing an additional 1,252,834 shares during the last quarter. LMR Partners LLP bought a new stake in Bausch Health Companies in the third quarter valued at $3,264,000. Clearline Capital LP acquired a new stake in Bausch Health Companies in the second quarter valued at approximately $6,881,000. Intact Investment Management Inc. acquired a new position in Bausch Health Companies during the third quarter worth $1,543,000. Finally, XTX Topco Ltd bought a new position in Bausch Health Companies in the 3rd quarter valued at about $938,000. 78.65% of the stock is owned by institutional investors and hedge funds.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.